NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.
News + EventsPCT, a NeoStem Company, Presented LOVO® Cell Processing System Data at IBC Life Sciences' Commercialization of Cell, Gene & Immunotherapies Conference December 15, 2014 - Learn MoreNeoStem's Subsidiary, Progenitor Cell Therapy, Receives AABB Re-Accreditation for its Allendale, NJ Manufacturing Facility December 8, 2014 - Learn MoreNeoStem and PCT, a NeoStem Company, to Present at Multiple December Conferences December 1, 2014 - Learn More
We are particularly encouraged by the results of our PreSERVE AMI trial both from our own reading of the in.... Read More